section name header

Indications

IM: IM:

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: facial flushing, rash

EENT: nasal onlyrhinitis, epistaxis, nasal irritation

GI: IM, SUBQnausea, vomiting

GU: IM, SUBQurinary frequency

Local: injection site reactions

MS: nasalarthralgia, back pain

Neuro: nasal onlyheadaches

Misc: MALIGNANCY, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Postmenopausal osteoporosis

Paget’s disease

Hypercalcemia

US Brand Names

Miacalcin

Action

  • Inhibits osteoclastic bone resorption and promotes renal excretion of calcium.
Therapeutic effects:
  • Decreased rate of bone turnover.
  • Lowering of serum calcium.

Classifications

Therapeutic Classification: hypocalcemics

Pharmacologic Classification: hormones

Pharmacokinetics

Absorption: Completely absorbed from IM and SUBQ sites. Rapidly absorbed from nasal mucosa; absorption is 3% compared with parenteral administration.

Distribution: Unknown.

Metabolism/Excretion: Rapidly metabolized in kidneys, blood, and tissues.

Half-Life: 40–90 min.

Canadian Brand Names

Calcimar

Time/Action Profile

ROUTEONSETPEAKDURATION
IM, SUBQunknown2 hr6–8 hr
Intranasalrapid31–39 minunknown

Effects on serum calcium; effects on serum alkaline phosphates and urinary hydroxyproline in Paget's disease may require 6–24 mo of continuous treatment.

Serum levels of administered calcitonin.



Patient/Family Teaching

Pronunciation

kal-si-TOE-nin